Sign up to save your podcasts
Or
Share Longevity Isn’t a Treatment—It’s a Strategy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Longevity Isn’t a Treatment—It’s a Strategy
“PRP contains everything the body needs to regenerate.” – Giuseppe Calloni
In this episode of Compound Wisdom, Steve Sood sits down with Giuseppe Calloni of RegenLab USA to break down what platelet-rich plasma (PRP) really is, how it’s made, and why Giuseppe believes the future of regenerative medicine is prevention—not just treatment.
Giuseppe shares a non-linear career path that starts in Milan, moves through a PhD in atomic physics in the UK, and spans oil & gas, chemical R&D, and biotech before he ultimately lands in regenerative medicine and becomes CEO. That “career without a plan” theme becomes a key thread: curiosity, learning, and global experience across France, Switzerland, China, and the U.S. shaped how he thinks about science, products, and patients.
From there, the conversation gets practical. Giuseppe explains RegenLab’s gel separation technology in simple terms: blood is drawn into a tube containing a specialized gel, spun in a centrifuge for about five minutes, and separated by density into layers—allowing clinicians to create platelet-rich plasma. He also highlights that PRP has existed for decades, expanding from early uses into sports medicine, injuries, hair restoration, aesthetics, gynecology, and orthopedics.
The episode then shifts into what makes RegenLab different in Giuseppe’s view: a data-first approach (patents, clinical data, publications) and a long-term strategy to navigate global regulation. Giuseppe describes the reality of waiting years for approvals—including a 10-year FDA timeline that eventually led to a PRP-based kit for diabetic chronic wounds being released with nationwide reimbursement. He argues the delays are frustrating but necessary if the goal is safety, efficacy, and real patient outcomes.
Finally, Steve and Giuseppe go wider: exosomes, stem cells, and the “hype cycle” in longevity. Giuseppe is candid about how exosomes became popular as a concept, but questions whether many products in the market are truly data-driven. He also explains why RegenLab stays focused on PRP and its next evolution—PRP plus tissue engineering approaches like hyaluronic acid scaffolds, and new minimally invasive implant ideas using electrospinning and 3D printing to help patients recover faster and avoid major surgeries. The throughline is clear: keep people moving, keep quality of life high, and prevent the decline before it becomes irreversible.
Takeaways
Giuseppe’s career path started in Milan and led to a PhD in atomic physics in the UK.
Curiosity drove him across oil & gas, chemical R&D, and then biotech.
He worked across Italy, France, Switzerland, China, and the U.S. before settling in America.
He became CEO at RegenLab after a collaboration that began when RegenLab was a client.
RegenLab is positioned as a science-based medical device company (patents, publications, clinical data).
PRP is created by separating blood components by density using a specialized gel + centrifuge process.
The gel transitions state under spinning, allowing clean layer separation in about five minutes.
After separation, the platelet concentration can be increased by inverting the tube multiple times.
PRP has been used in the market since the 1970s and expanded into many clinical applications.
Use cases discussed include sports injuries, pain relief, hair loss, aesthetics, gynecology, and knee osteoarthritis.
Giuseppe claims PRP can regenerate at the cellular level via growth factors in platelets.
He says PRP is the only truly effective hair regeneration treatment currently.
RegenLab’s PRP platform includes “PRP plus” approaches and tissue engineering directions.
Combining PRP with hyaluronic acid can act as a scaffold and prolong time between treatments.
Giuseppe emphasizes prevention as the core direction of regenerative medicine.
RegenLab expanded manufacturing across Switzerland, France, and the U.S. to manage global regulation and supply chains.
He says the company has treated roughly 2–3 million patients over 20+ years.
A PRP-based kit for diabetic chronic wounds took about 10 years to clear the FDA, then launched with reimbursement.
Regulatory pathways vary widely: US, China, and Europe have different standards and timelines.
Giuseppe is skeptical of exosome trends that are more marketing-led than data-led.
He sees stem cells as a different category with sourcing and ethical questions.
He believes minimally invasive repair (electrospinning + 3D printing implants) is the next leap.
He links public health challenges (aging population, diabetes, lifestyle) to the urgency of prevention-first solutions.
His “make it stick” answer: stay curious, resilient, and future-focused.
Chapters
00:00 – Welcome and Giuseppe’s background in Milan
00:15 – PhD in the UK, curiosity, and early career shifts
01:40 – Global travel and working across countries and cultures
02:44 – RegenLab’s origin story and science-first positioning
03:09 – Gel separation technology explained (blood → centrifuge → layers)
04:20 – What PRP is and how platelet-rich plasma is formed
05:13 – PRP’s long history and expanding use cases
06:16 – Patents, publications, and clinical data focus
06:48 – Why PRP is “blowing up” and where it’s used
07:01 – PRP’s role in healing, regeneration, and growth factors
08:59 – PRP + hyaluronic acid and the tissue engineering evolution
10:50 – Global reach: manufacturing strategy and distribution footprint
11:45 – Patient scale: 2–3 million treated over 20+ years
12:41 – 10-year FDA timeline for diabetic chronic wounds + reimbursement
14:24 – Differences between FDA, Europe, and China regulation
16:26 – PRP vs exosomes vs stem cells (ELI5 framing)
17:29 – Exosomes: sourcing, viability, and the marketing vs data debate
19:00 – Stem cells: source questions and why RegenLab stays PRP-focused
20:49 – RegenLab’s 3–5 year plan: PRP-plus pipeline and knee OA focus
22:39 – Tissue engineering + minimally invasive implants (electrospinning, 3D printing)
23:25 – Where regenerative medicine is going: prevention and quality of life
24:55 – Diabetes, lifestyle, and why the prevention conversation matters
26:44 – PRP in wound care and why it’s impactful in chronic wounds
27:44 – Wound care market size and faster healing vs alternatives
29:42 – Blind question: “How do you make it stick?”
30:45 – Giuseppe’s question for the next guest: globalization outlook
31:49 – Closing and thanks
View all episodes
By Dante McClain“PRP contains everything the body needs to regenerate.” – Giuseppe Calloni
In this episode of Compound Wisdom, Steve Sood sits down with Giuseppe Calloni of RegenLab USA to break down what platelet-rich plasma (PRP) really is, how it’s made, and why Giuseppe believes the future of regenerative medicine is prevention—not just treatment.
Giuseppe shares a non-linear career path that starts in Milan, moves through a PhD in atomic physics in the UK, and spans oil & gas, chemical R&D, and biotech before he ultimately lands in regenerative medicine and becomes CEO. That “career without a plan” theme becomes a key thread: curiosity, learning, and global experience across France, Switzerland, China, and the U.S. shaped how he thinks about science, products, and patients.
From there, the conversation gets practical. Giuseppe explains RegenLab’s gel separation technology in simple terms: blood is drawn into a tube containing a specialized gel, spun in a centrifuge for about five minutes, and separated by density into layers—allowing clinicians to create platelet-rich plasma. He also highlights that PRP has existed for decades, expanding from early uses into sports medicine, injuries, hair restoration, aesthetics, gynecology, and orthopedics.
The episode then shifts into what makes RegenLab different in Giuseppe’s view: a data-first approach (patents, clinical data, publications) and a long-term strategy to navigate global regulation. Giuseppe describes the reality of waiting years for approvals—including a 10-year FDA timeline that eventually led to a PRP-based kit for diabetic chronic wounds being released with nationwide reimbursement. He argues the delays are frustrating but necessary if the goal is safety, efficacy, and real patient outcomes.
Finally, Steve and Giuseppe go wider: exosomes, stem cells, and the “hype cycle” in longevity. Giuseppe is candid about how exosomes became popular as a concept, but questions whether many products in the market are truly data-driven. He also explains why RegenLab stays focused on PRP and its next evolution—PRP plus tissue engineering approaches like hyaluronic acid scaffolds, and new minimally invasive implant ideas using electrospinning and 3D printing to help patients recover faster and avoid major surgeries. The throughline is clear: keep people moving, keep quality of life high, and prevent the decline before it becomes irreversible.
Takeaways
Giuseppe’s career path started in Milan and led to a PhD in atomic physics in the UK.
Curiosity drove him across oil & gas, chemical R&D, and then biotech.
He worked across Italy, France, Switzerland, China, and the U.S. before settling in America.
He became CEO at RegenLab after a collaboration that began when RegenLab was a client.
RegenLab is positioned as a science-based medical device company (patents, publications, clinical data).
PRP is created by separating blood components by density using a specialized gel + centrifuge process.
The gel transitions state under spinning, allowing clean layer separation in about five minutes.
After separation, the platelet concentration can be increased by inverting the tube multiple times.
PRP has been used in the market since the 1970s and expanded into many clinical applications.
Use cases discussed include sports injuries, pain relief, hair loss, aesthetics, gynecology, and knee osteoarthritis.
Giuseppe claims PRP can regenerate at the cellular level via growth factors in platelets.
He says PRP is the only truly effective hair regeneration treatment currently.
RegenLab’s PRP platform includes “PRP plus” approaches and tissue engineering directions.
Combining PRP with hyaluronic acid can act as a scaffold and prolong time between treatments.
Giuseppe emphasizes prevention as the core direction of regenerative medicine.
RegenLab expanded manufacturing across Switzerland, France, and the U.S. to manage global regulation and supply chains.
He says the company has treated roughly 2–3 million patients over 20+ years.
A PRP-based kit for diabetic chronic wounds took about 10 years to clear the FDA, then launched with reimbursement.
Regulatory pathways vary widely: US, China, and Europe have different standards and timelines.
Giuseppe is skeptical of exosome trends that are more marketing-led than data-led.
He sees stem cells as a different category with sourcing and ethical questions.
He believes minimally invasive repair (electrospinning + 3D printing implants) is the next leap.
He links public health challenges (aging population, diabetes, lifestyle) to the urgency of prevention-first solutions.
His “make it stick” answer: stay curious, resilient, and future-focused.
Chapters
00:00 – Welcome and Giuseppe’s background in Milan
00:15 – PhD in the UK, curiosity, and early career shifts
01:40 – Global travel and working across countries and cultures
02:44 – RegenLab’s origin story and science-first positioning
03:09 – Gel separation technology explained (blood → centrifuge → layers)
04:20 – What PRP is and how platelet-rich plasma is formed
05:13 – PRP’s long history and expanding use cases
06:16 – Patents, publications, and clinical data focus
06:48 – Why PRP is “blowing up” and where it’s used
07:01 – PRP’s role in healing, regeneration, and growth factors
08:59 – PRP + hyaluronic acid and the tissue engineering evolution
10:50 – Global reach: manufacturing strategy and distribution footprint
11:45 – Patient scale: 2–3 million treated over 20+ years
12:41 – 10-year FDA timeline for diabetic chronic wounds + reimbursement
14:24 – Differences between FDA, Europe, and China regulation
16:26 – PRP vs exosomes vs stem cells (ELI5 framing)
17:29 – Exosomes: sourcing, viability, and the marketing vs data debate
19:00 – Stem cells: source questions and why RegenLab stays PRP-focused
20:49 – RegenLab’s 3–5 year plan: PRP-plus pipeline and knee OA focus
22:39 – Tissue engineering + minimally invasive implants (electrospinning, 3D printing)
23:25 – Where regenerative medicine is going: prevention and quality of life
24:55 – Diabetes, lifestyle, and why the prevention conversation matters
26:44 – PRP in wound care and why it’s impactful in chronic wounds
27:44 – Wound care market size and faster healing vs alternatives
29:42 – Blind question: “How do you make it stick?”
30:45 – Giuseppe’s question for the next guest: globalization outlook
31:49 – Closing and thanks